Safety of biologic agents in elderly patients with rheumatoid arthritis

Atsuko Murota, Yuko Kaneko, Kunihiro Yamaoka, Tsutomu Takeuchi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective. To clarify the safety of biologics in elderly patients with rheumatoid arthritis. Methods. Biologics were analyzed for safety in relation to age in 309 patients. Results. Young (< 65 yrs old, n = 174), elderly (65-74 yrs old, n = 86), and older elderly patients (? 75 yrs old, n = 49) were enrolled. Although the incidence of adverse events causing treatment withdrawal was significantly higher in elderly and old elderly compared with young patients, no difference was found between elderly and older elderly patients. Pulmonary complications were independent risk factors. Conclusion. Old patients require special attention, although the safety of biologics in those ? 75 years old and 65-74 was comparable.

Original languageEnglish
Pages (from-to)1984-1988
Number of pages5
JournalJournal of Rheumatology
Volume43
Issue number11
DOIs
Publication statusPublished - 2016 Nov 1

Keywords

  • ADVERSE EVENTS
  • BIOLOGICAL THERAPY
  • ELDERLY PATIENT
  • RHEUMATOID ARTHRITIS
  • SAFETY

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology

Fingerprint Dive into the research topics of 'Safety of biologic agents in elderly patients with rheumatoid arthritis'. Together they form a unique fingerprint.

  • Cite this